IMPROVEMENT IN AIDS PATIENTS ON PEPTIDE T

The Lancet

Volumn 334, Issue 8656, 1989, Pages 226-227

  Bridge, T Peter ^a,b   Heseltine, PeterN R ^a,b   Parker, ElizabethS ^a,b   Eaton, Elaine ^a,b   Ingraham, LoringJ ^a,b   Gill, Mark ^a,b   Ruff, Michael ^a,b   Pert, CandaceB ^a,b   Goodwin, FrederickK ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE T;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; DRUG EVALUATION; HALF-LIFE; HUMAN; MIDDLE AGE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDE T;

EID: 0024359962     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(89)90416-9     Document Type: Letter

References (5)

1. Octopeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity
2. CD4 receptor binding peptides that block HIV infectivity cause monocyte chemotaxis
3. Peptide T is core HIV envelope required for CD4 receptor attachment
4. Neuronal killing by the enveloped protein of HIV and its prevention by vasoactive intestinal peptide
5. Peptide T sequences prevent neuronal cell death produced by the protein (gp 120) of the Human Immunodeficiency Virus